Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
47 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Visceral Pain - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Visceral Pain - Pipeline Review, H2 2014', provides an overview of the Visceral Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Visceral Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Visceral Pain and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Visceral Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Visceral Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Visceral Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Visceral Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Visceral Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Visceral Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Visceral Pain Overview 6 Therapeutics Development 7 Pipeline Products for Visceral Pain - Overview 7 Pipeline Products for Visceral Pain - Comparative Analysis 8 Visceral Pain - Therapeutics under Development by Companies 9 Visceral Pain - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Visceral Pain - Products under Development by Companies 12 Visceral Pain - Companies Involved in Therapeutics Development 13 Nektar Therapeutics 13 Astellas Pharma Inc. 14 Neurim Pharmaceuticals Ltd 15 Grunenthal GmbH 16 Trevena, Inc. 17 Hydra Biosciences, Inc. 18 GIcare Pharma Inc 19 Istituto Italiano di Tecnologia 20 Visceral Pain - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 25 Assessment by Route of Administration 28 Assessment by Molecule Type 29 Drug Profiles 30 GIC-1001 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 piromelatine - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 HC-030031 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecules to Agonize Kappa Opioid Receptor for CNS Disorder - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 NeuP-12 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Agonize Delta Opioid Receptor for CNS Disorders - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 NKTR-195 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 ASP-7663 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 URB-937 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 RO-656570 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Visceral Pain - Recent Pipeline Updates 43 Visceral Pain - Dormant Projects 44 Visceral Pain - Discontinued Products 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 47 Disclaimer 47
List of Tables Number of Products under Development for Visceral Pain, H2 2014 7 Number of Products under Development for Visceral Pain - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Clinical Stage Development, H2 2014 10 Comparative Analysis by Early Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Visceral Pain - Pipeline by Nektar Therapeutics, H2 2014 13 Visceral Pain - Pipeline by Astellas Pharma Inc., H2 2014 14 Visceral Pain - Pipeline by Neurim Pharmaceuticals Ltd, H2 2014 15 Visceral Pain - Pipeline by Grunenthal GmbH, H2 2014 16 Visceral Pain - Pipeline by Trevena, Inc., H2 2014 17 Visceral Pain - Pipeline by Hydra Biosciences, Inc., H2 2014 18 Visceral Pain - Pipeline by GIcare Pharma Inc, H2 2014 19 Visceral Pain - Pipeline by Istituto Italiano di Tecnologia, H2 2014 20 Assessment by Monotherapy Products, H2 2014 21 Number of Products by Stage and Target, H2 2014 24 Number of Products by Stage and Mechanism of Action, H2 2014 27 Number of Products by Stage and Route of Administration, H2 2014 28 Number of Products by Stage and Molecule Type, H2 2014 29 Visceral Pain Therapeutics - Recent Pipeline Updates, H2 2014 43 Visceral Pain - Dormant Projects, H2 2014 44 Visceral Pain - Discontinued Products, H2 2014 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
